Please login to the form below

Not currently logged in
Email:
Password:

SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

Roche’s first TIGIT data points to benefit when added to Tecentriq

Roche’s first TIGIT data points to benefit when added to Tecentriq

alone in extensive-stage small cell lung cancer (ES-SCLC).

Latest news

More from news
Approximately 5 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.  .

  • Deal Watch April 2016 Deal Watch April 2016

    Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.

  • Deal Watch November 2015 Deal Watch November 2015

    July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

The big issue
Whether you want to lead or follow, you need to understand the elephant in the C-suite...
INFOGRAPHIC 02: The Importance of clinical study websites
Here’s a infographic of why clinical study websites are important to patient recruitment and retention strategies…...
Working with, Advocating for, and Empowering Patients
A holistic view of how to work with patients virtually...

Infographics